Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects - Pettitt, A R; Matutes, E; Oscier, D (Leukemia, 2006)